the incidence of arterial and venous thromboembolic complications was compared in 224 renal allograft recipients who were prospectively randomized and stratified by risk to treatment with either cyclosporine-prednisone ( csa-p ) ( n = 117 ) or azathioprine-prednisone-antilymphocyte globulin ( aza-p-alg ) ( n = 107 ) .
C0338291
cyclosporine-prednisone
C0032952
prednisone